GeNeuro Wins European Patent for ALS Treatment Invention

GeNeuro, a subsidiary of NRx Pharmaceuticals, has been awarded a European patent for its monoclonal antibody GNK-301, which targets the reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env) linked to ALS. The patent covers the prevention of neurotoxic effects of K Env in nonclinical subjects and human motor neuron cells. GeNeuro plans to initiate human Phase I trials in patients with ALS in the second half of 2027 in the US and Europe. The company will participate in a conference on "HERVs and Humanity" this weekend, focusing on the understanding and treatment of HERV-induced diseases, including ALS, Multiple Sclerosis, Optic Neuritis, and Schizophrenia.